PAN is a monoclonal antibody that acts against the epidermal growth factor receptor (EGFR) [37], which presents, especially, dermatological adverse reactions, such as less severe and frequent skin rashes, compared to cytostatic treatments. This evidence concerns the gene ADA2 and neoplasm.